Table 2 Comorbidities in the UHH cohort
From: Pirfenidone improves survival in IPF: results from a real-life study
Comorbidities | N = 82 |
|---|---|
Systemic Hypertension | 58 (64%) |
Gastroesophageal Reflux Disease | 42 (47%) |
Ischemic Heart Disease | 27 (30%) |
Heart Failure | 25 (28%) |
Diabetes Mellitus | 24 (27%) |
Obstructive Sleep Apnea-Hypopnea Syndrome | 23 (26%) |
Depression | 21 (23%) |
Emphysema | 19 (21%) |
Pulmonary Hypertension | 12 (13%) |
Lung Cancer | 2 (2%) |
Venous Thromboembolism | 1 (1%) |